CD274 and head and neck squamous cell carcinoma: Using the VENTANA PD-L1 (SP263) Assay, the combined TC ≥ 50%/IC ≥ 25% algorithm was associated with increased durvalumab efficacy in R/M HNSCC and discrimination of patients with survival benefit from durvalumab treatment.